Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride

Author(s):  Zur Eyal

Issue:  Sep/Oct 2011 - Volume 15, Number 5
View All Articles in Issue

Page(s):  358-366

Note:  Electronic version includes supplemental material.

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 1
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 2
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 3
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 4
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 5
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 6
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 7
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 8
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 9

Download in electronic PDF format for $65

Abstract:  Infantile hemangiomas are the most common benign tumors of infancy. Although a well-known pathology with substantial medical experience, the etiology and pathogenesis of this disease is not exactly known. In most cases, the pathology regresses spontaneously around the age of 12 months without complications and without the need of medical treatment. However, sometimes the complications are severe and even life threatening, and medical intervention is mandatory. Until 2008, the first-line treatment of this pathology was primarily oral and topical corticosteroids, with suboptimal results and unpleasant side effects. The serendipitous discovery of the unusual effect of oral propranolol hydrochloride on infantile hemangiomas, causes a mini-revolution in the pediatric dermatology society world wide. Propranolol hydrochloride not only stopped the proliferative phase of the tumor but also resulted in a remarkable shrinkage and substantial improvement in the clinical parameters of the tumor, including life-threatening complications, with minimal side effects. In this article, the compounding pharmacist can learn comprehensively about this pathology, and about the current accumulative knowledge in the treatment of oral propranolol hydrochloride. Topical treatment with the use of beta blockers in the treatment of infantile hemangiomas is discussed in Part 2 of this article.

Related Keywords: Eyal Zur, RPh, MBA, infants, children, formulation, benign vascular tumor, propranolol hydrochloride, beta blocker, complications, skin disorders, PHACE syndrome, risk factors, adverse effects, angiogenesis, blood vessels, vasculogenesis, endothelial progenitor cell proliferation, lymphangioma, intractable diffuse lymphangiomatosis

Related Categories: DERMATOLOGY, FORMULATIONS, PEDIATRICS, CARDIOLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
Sep/Oct 2011
Pg. 358-366

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Oral Mucositis: Etiology and Clinical and Pharmaceutical Management
Zur Eyal
Jan/Feb 2012
Pg. 22-33

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum
Zur Eyal
Mar/Apr 2012
Pg. 117-124

Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
Jan/Feb 2014
Pg. 14-19